Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Third Quarter 2023 Financial Results

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year ...
October 31, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
October 18, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting

SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
September 14, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
August 10, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Second Quarter 2023 Financial Results

40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI...
August 07, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize...
July 25, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

SOLANA BEACH, Calif., and CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI)...
June 14, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment

SOLANA BEACH, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
May 15, 2023 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports First Quarter 2023 Financial Results

Net product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE...
May 09, 2023 07:00 ET | Source: Evoke Pharma, Inc.

Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

SOLANA BEACH, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI)...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right